143 related articles for article (PubMed ID: 34028091)
21. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
Saini N; Grewal AS; Lather V; Gahlawat SK
Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of 2,3-dihydro-[1,4]dioxino[2,3-f]quinazoline derivatives as EGFR inhibitors.
Qin X; Yang L; Liu P; Yang L; Chen L; Hu L; Jiang M
Bioorg Chem; 2021 May; 110():104743. PubMed ID: 33714020
[TBL] [Abstract][Full Text] [Related]
23. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
[TBL] [Abstract][Full Text] [Related]
24. Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).
Bhatia P; Sharma V; Alam O; Manaithiya A; Alam P; Kahksha ; Alam MT; Imran M
Eur J Med Chem; 2020 Oct; 204():112640. PubMed ID: 32739648
[TBL] [Abstract][Full Text] [Related]
25. The Performance of Several Docking Programs at Reproducing Protein-Macrolide-Like Crystal Structures.
Castro-Alvarez A; Costa AM; Vilarrasa J
Molecules; 2017 Jan; 22(1):. PubMed ID: 28106755
[TBL] [Abstract][Full Text] [Related]
26. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
27. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
28. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
29. Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening.
Ornnork N; Kiriwan D; Lirdprapamongkol K; Choowongkomon K; Svasti J; Eurtivong C
J Mol Graph Model; 2020 Sep; 99():107639. PubMed ID: 32534372
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W
Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040
[TBL] [Abstract][Full Text] [Related]
31. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
[TBL] [Abstract][Full Text] [Related]
32. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
[TBL] [Abstract][Full Text] [Related]
33. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
34. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
Zhang Y; Zhang Y; Liu J; Chen L; Zhao L; Li B; Wang W
Bioorg Med Chem Lett; 2017 Apr; 27(7):1584-1587. PubMed ID: 28238614
[TBL] [Abstract][Full Text] [Related]
36. Designing and
Patil SM; Shashikant B
Curr Drug Discov Technol; 2023; 20(6):47-59. PubMed ID: 37291789
[TBL] [Abstract][Full Text] [Related]
37. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
39. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
Zhang B; Liu Z; Xia S; Liu Q; Gou S
Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]